Evidence map›Paper›PMID 41751522›Full record

ReviewGenes2026

DDX10 RNA Helicase: Structure, Function, and Oncogenic Roles Across Solid and Hematologic Tumors.

Giorgia Isinelli, Genny Scacci, Arianna Capocchia, Carla Emiliani, Cristina Mecucci, Roberta La Starza, Danika Di Giacomo

Abstract readReview
In one paragraph

Review in Genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Giorgia IsinelliDepartment of Chemistry, Biology and Biotechnology, University of Perugia, 06100 Perugia, Italy.ORCID 0000-0002-1798-1576
Genny ScacciDepartment of Chemistry, Biology and Biotechnology, University of Perugia, 06100 Perugia, Italy.ORCID 0009-0008-2887-6457
Arianna CapocchiaDepartment of Chemistry, Biology and Biotechnology, University of Perugia, 06100 Perugia, Italy.ORCID 0009-0003-4496-9905
Carla EmilianiDepartment of Chemistry, Biology and Biotechnology, University of Perugia, 06100 Perugia, Italy.
Cristina MecucciHematology and Bone Marrow Transplantation Unit, Department of Medicine and Surgery, CREO, Azienda Ospedaliera di Perugia, University of Perugia, 06100 Perugia, Italy.
Roberta La StarzaHematology and Bone Marrow Transplantation Unit, Department of Medicine and Surgery, CREO, Azienda Ospedaliera di Perugia, University of Perugia, 06100 Perugia, Italy.ORCID 0000-0001-5854-9846
Danika Di GiacomoDepartment of Chemistry, Biology and Biotechnology, University of Perugia, 06100 Perugia, Italy.ORCID 0000-0002-5558-7967

Funding

National Recovery and Resilience Plan (NRRP), Mission 4, Component 2, Investment 1.1 CUP J53D23017510001
6 · The paper itself

Abstract

DEAD-box (DDX) RNA helicases are essential regulators of RNA metabolism and gene expression. Among them, DDX10 remains poorly characterized despite growing evidence supporting its involvement in human diseases. This review provides a comprehensive analysis of DDX10, from its structural and functional features to its emerging roles in solid tumors and hematologic malignancies. We discuss how DDX10, through its conserved domains, contributes to pre-rRNA processing, ribosome biogenesis, and cell proliferation, and explore potential links between DDX10 and processes such as liquid-liquid phase separation (LLPS) and epigenetic regulation, which may underlie its roles in cancer cell plasticity and stress response. We argue that the dysregulation of these fundamental cellular processes positions DDX10 as a focal point where aberrant RNA metabolism and altered molecular condensates converge to disrupt transcriptional homeostasis and drive oncogenic transformation. Aberrant DDX10 expression is a recurrent feature across multiple cancers, where it promotes tumor progression, therapy resistance, and poor prognosis. Moreover, DDX10 participates in oncogenic fusion events, most notably the NUP98::DDX10 fusion identified in a subset of acute myeloid leukemias, which drives leukemogenesis by disrupting transcriptional regulation and cellular differentiation. Given its tumor-associated expression and diverse biological functions, DDX10 is increasingly recognized as a potential diagnostic biomarker and a promising target for therapeutic strategies. By consolidating current knowledge under this unifying framework, this review highlights the multifaceted roles of DDX10 in cancer biology, advocating further research into its molecular functions and translational potential.

Indexed as

DEAD-box RNA HelicasesHematologic NeoplasmsNeoplasmsAnimalsEpigenesis, GeneticGene Expression Regulation, NeoplasticHumansDDX10 protein, humanDEAD-box RNA Helicasesacute myeloid leukemia (AML)DDX10DEAD-box RNA helicaseepigenetic regulationliquid–liquid phase separation (LLPS)NUP98::DDX10 fusiononcogenic transformationribosome biogenesissolid tumorstumor biomarker

Identifiers

PMID41751522
PMCPMC12940211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.